Specialty Pharmacy

Patients prescribed drugs for indications that the FDA has not approved face a 44% greater risk for adverse drug events.

A man went into a Rite Aid seeking treatment for diarrhea. Next thing he knew, he was detained at a medical center for 7 hours while he was tested for Ebola.

Multiple myeloma therapeutic spending forecast to his $22.4 billion by 2023.

Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses methods to overcome the challenge of high out-of-pocket costs that can have a negative impact on patient medication adherence.

Manganese may offer cost-effective alternative in drug development.

Combination of risk factors and PsA disease activity found increase dangers of cardiovascular disease.

Combination of everolimus and small molecule compound significantly reduces viability of cancer cells.

The once daily oral medication is for use with Sovaldi with or without ribavirin or in combination with peginterferon alfa and ribavirin.

Heritability plays more of a factor in pediatric-onset autoimmune diseases than in adult diseases.

Spending on brand prescription drugs increased despite a 16% decrease in the use of these drugs.

The FDA is reviewing Gilead Sciences' new drug application (NDA) for a fixed dose combination of sofosbuvir (Solvadi) and velpatasvir to treat genotype 1-6 hepatitis C virus infection.

Research shows cells are unable to divide and invade at the same time.

Drugs are delivered via the low-resistance Neohaler inhaler.

Top news of the week in cancer drug development.

Top stories of the week on Specialty Pharmacy Times.

Immunosuppressive drug linked to central nervous system lymphoma in solid organ transplant patients.

Rhabdomyosarcoma is the most common soft tissue sarcoma in children.

Study suggests superior efficacy from older PsA drugs.

GAO made recommendations for safeguards to prevent enrollees from having Medicaid and exchange coverage at the same time.

A specialty mail-order pharmacy that filled prescriptions for Valeant has closed amid reports of improper behavior.

Ligand-guided protein cages kill more than 70 percent of lung cancer cells during testing.

Study may lead to enhanced efficacy of breast cancer drugs.

Strategy reduces cost without compromising RA symptom control.

Blood test offers insight into how well a drug is working during the course of cancer treatment.

A woman's hormonal status may resume balance.

Pharmacists may be able to reduce hospital readmissions by calling discharged patients to check in about their medications.

T-VEC is a first-in-class immunotherapy for unresectable cutaneous, subcutaneous, and nodal lesions in advanced melanoma.

Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses the services offered by Diplomat's HUB EnvoyHealth program.